GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.
Adult
Aged
Aged, 80 and over
Animals
Antimetabolites, Antineoplastic
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cells, Cultured
Cohort Studies
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Female
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Glyceraldehyde-3-Phosphate Dehydrogenases
/ genetics
HEK293 Cells
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Middle Aged
Prednisone
/ therapeutic use
Prognosis
Retrospective Studies
Rituximab
/ therapeutic use
Treatment Outcome
Vincristine
/ therapeutic use
Young Adult
DLBCL
GAPDH
L-asparaginase
OxPhos
R-CHOP
glycolysis
mTOR
predictive marker
Journal
Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170
Informations de publication
Date de publication:
04 06 2019
04 06 2019
Historique:
received:
21
09
2018
revised:
21
12
2018
accepted:
06
02
2019
pubmed:
5
3
2019
medline:
15
8
2020
entrez:
5
3
2019
Statut:
ppublish
Résumé
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease treated with anti-CD20-based immuno-chemotherapy (R-CHOP). We identified that low levels of GAPDH predict a poor response to R-CHOP treatment. Importantly, we demonstrated that GAPDH
Identifiants
pubmed: 30827861
pii: S1550-4131(19)30066-X
doi: 10.1016/j.cmet.2019.02.002
pii:
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Glyceraldehyde-3-Phosphate Dehydrogenases
EC 1.2.1.-
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243-1257.e10Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.